drugset / Trial / NCT05490836
Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is aimed to explore the safety and efficacy of the pulse usage , comparing to continuous usage, of Peginterferon alfa-2b Injection (PEG IFN α-2b) Combined With tenofovir alafenamide (TAF) in treatment of naive chronic hepatitis B patients with HBeAg negative.
Timeline
- Start
- 2022-09
- Primary completion
- 2024-08
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 135 ug | Subcutaneous |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Background | tenofovir alafenamide | Small molecule | — | Oral |